Altan

DGAP-News: Mynaric withdraws from China to serve security interests of its core markets

Retrieved on: 
Friday, July 31, 2020

Munich, July 31, 2020 - Mynaric announced yesterday that, with immediate effect, it is to cease its business activities in China.

Key Points: 
  • Munich, July 31, 2020 - Mynaric announced yesterday that, with immediate effect, it is to cease its business activities in China.
  • Yesterday's announcement comes as a consequence of a notification by the German government that clearly prohibits Mynaric from delivering laser communication hardware to China.
  • Consequently, Mynaric acknowledges this strategic importance and has acted responsibly by committing to put the interests of national security of its core markets above all other considerations.
  • - Bulent Altan, CEO
    Mynaric considers its clear commitment to national interests of its core markets as critical to its business success.

Altan Pharma Submits New Drug Application for Acetaminophen Solution for Infusion for Treatment of Pain and Reduction of Fever

Retrieved on: 
Thursday, February 7, 2019

Altan has developed a unique, ready-to-use formulation that does not require deoxygenation and that can be packaged in flexible plastic containers, which are preferred by hospitals.

Key Points: 
  • Altan has developed a unique, ready-to-use formulation that does not require deoxygenation and that can be packaged in flexible plastic containers, which are preferred by hospitals.
  • Altan announced last April that the United States Patent and Trademark Office (USPTO) had awarded the Company two patents covering its unique formulation of intravenous acetaminophen.
  • Altan has manufactured and sold more than 200 million units of its intravenous acetaminophen formulation in the above non-US markets.
  • Altan Pharma Ltd.is a privately held, specialty pharmaceutical company that develops, manufactures and commercializes injectable drugs for the hospital and other provider segments.